Recent Updates — CLVLF

Clinuvel Pharmaceuticals Limited has submitted a marketing authorization dossier for its second pharmaceutical product, NEURACTHEL Instant (tetracosactide), to national European regulators under the European decentralised procedure. The filing targets initial approval in three key EU Member States based on commercial priorities and prescriber demand. If approved, Clinuvel will be able to commercialise the branded generic formulation as a prescription drug in those markets. The company expects first formal feedback from regulators in approximately four months following dossier validation. Clinuvel is a global biopharmaceutical company focused on developing and delivering innovative therapies for patients with genetic, metabolic, and dermatological disorders.

Clinuvel Pharmaceuticals provided a commercial update on the vitiligo market, benchmarking its lead therapy SCENESSE against narrowband UVB and JAK inhibitors. The filing details clinical efficacy data for competitors, noting that topical ruxolitinib achieved F-VASI50 in 45-50% of patients at week 24, while systemic upadacitinib reached T-VASI50 in approximately 20% at week 48. Clinuvel anticipates topline results from its pivotal CUV105 study for extensive vitiligo in December 2026 and expects the start of the subsequent CUV107 study in November 2026. The company has scaled North American infrastructure and engaged over 100 potential specialty centers. Clinuvel Pharmaceuticals is a biopharmaceutical company developing therapies for genetic, metabolic, and dermatological disorders.